ArticleClinical cancer research : an official journal of the American Association for Cancer Research2021
PET Imaging of TIGIT Expression on Tumor-Infiltrating Lymphocytes.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Advancements in non-invasive visualization of the immune checkpoint TIGIT: a systematic review.European journal of nuclear medicine and molecular imaging · 2025Pooled it
- Challenges in tracer development for tumor microenvironment (TME) imaging.European journal of nuclear medicine and molecular imaging · 2026Review
- A SLC7A5-Specific Near-Infrared Fluorescent Probe for Cancer-Targeted Imaging Applications.Journal of fluorescence · 2026Article
- Emerging ImmunoPET probes for precision cancer immunotherapy: molecular targets and translational applications.Frontiers in oncology · 2026Review
- Imaging antigen processing and presentation in cancer.Immunotherapy advances · 2025Review
- Development and characterisation of [European journal of nuclear medicine and molecular imaging · 2025Article
- Peptide PET Imaging: A Review of Recent Developments and a Look at the Future of Radiometal-Labeled Peptides in Medicine.Chemical & biomedical imaging · 2024Review
- Single-cell RNA sequencing unveils tumor heterogeneity and immune microenvironment between subungual and plantar melanoma.Scientific reports · 2024Article
- ImmunoPET imaging of TIGIT in the glioma microenvironment.Scientific reports · 2024Article
- ImmunoPET provides a novel way to visualize the CD103EJNMMI research · 2024Review
- Illuminating immunotherapy response via precision T cell-targeted PET imaging.Frontiers in medicine · 2024Review
- TIGIT, a novel immune checkpoint therapy for melanoma.Cell death & disease · 2023Review
- Recent Trends in Diagnostic Biomarkers of Tumor Microenvironment.Molecular imaging and biology · 2023Review
- Peptide-based PET imaging agent of tumor TIGIT expression.EJNMMI research · 2023Article
- Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT.Frontiers in immunology · 2023Article
- Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy.Frontiers in medicine · 2023Review
- The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients.Cancers · 2022Review
- Imaging cellular immunotherapies and immune cell biomarkers: from preclinical studies to patients.Journal for immunotherapy of cancer · 2022Review
- Molecular imaging to support cancer immunotherapy.Journal for immunotherapy of cancer · 2022Review
- What Inhibits Natural Killers' Performance in Tumour.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purposeTherapeutic checkpoint inhibitors on tumor-infiltrating lymphocytes (TIL) are being increasingly utilized in the clinic. The T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is an inhibitory receptor expressed on T and natural killer cells. The TIGIT signaling pathway is an alternative target for checkpoint blockade to current PD-1/CTLA-4 strategies. Elevated TIGIT expression in the tumor microenvironment correlates with better therapeutic responses to anti-TIGIT therapies in preclinical models. Therefore, quantifying TIGIT expression in tumors is necessary for determining whether a patient may respond to anti-TIGIT therapy. PET imaging of TIGIT expression on TILs can therefore aid diagnosis and in monitoring therapeutic responses. EXPERIMENTAL
designAntibody-based TIGIT imaging radiotracers were developed with the PET radionuclides copper-64 (
resultsTwo anti-TIGIT probes were developed and exhibited immunoreactivity of >72%, serum stability of >95%, and specificity for TIGIT with both mouse TIGIT-expressing HeLa cells and
conclusionsThis study develops and validates novel TIGIT-specific
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.